TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11181667

Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg/m(2)/d
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Dexamethasone 18 mg/m(2)/d
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Dexamethasone 150 mg/m(2)/d
Number of subjects: 369

Group type: COMPARATOR
Intervention: Standard-dose corticosteroids (prednisolone 40 mg/m(2)/d or dexamethasone < 6 mg/m(2)/d)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (dexamethasone 18 or 150 mg/m(2)/d)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Standard-dose corticosteroids
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 369
Study: 9134141

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg, maximum dose 12 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 7700067

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 3428347

Group type: EXPERIMENTAL
Intervention: Oral administration of 750 mg theophylline (2 capsules Euphylong 375)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous aminophylline infusion corresponding to 506 mg theophylline over 8 h (63 mg.h‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous aminophylline infusion corresponding to 749 mg theophylline over 14 h, with a reduction in infusion rate from 69 to 33 mg.h‐1 after 8 h
Number of subjects: 0
Study: 29167980

Group type: EXPERIMENTAL
Intervention: Percutaneous platelet concentrate (PC) injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 40
Study: 28461350

Group type: EXPERIMENTAL
Intervention: Improved communication and behaviorally informed nudges
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25746022

Group type: EXPERIMENTAL
Intervention: Early invasive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed invasive approach
Number of subjects: 0
Study: 24282871

Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Regular toothpaste plus 1.4% potassium oxalate mouthrinse (LADS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Crest Cavity Protection Regular toothpaste
Number of subjects: 56

Group type: COMPARATOR
Intervention: Colgate Cavity Protection Regular toothpaste
Number of subjects: 56
Study: 22008088

Group type: EXPERIMENTAL
Intervention: Fusion with a supplemental flexible pedicle screw system to protect the adjacent segment ("topping off")
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fusion
Number of subjects: 0
Study: 18208741

Group type: EXPERIMENTAL
Intervention: Biomaterial to strengthen laparotomy closures in high-risk patients
Number of subjects: 0
Study: 17090992

Group type: EXPERIMENTAL
Intervention: 100 mg of isoflavone (soybean) and 1,500 mg of calcium for nine months
Number of subjects: 38

Group type: COMPARATOR
Intervention: 1,500 mg of calcium only for nine months
Number of subjects: 38
Study: 12950424

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 44
Study: 10802159

Group type: EXPERIMENTAL
Intervention: Multiple insulin injection therapy (MIT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional insulin injection therapy (CIT)
Number of subjects: 110
Study: 9162448

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (50 mmol/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-sodium diet (250 mmol/day)
Number of subjects: 30
Study: 1999883

Group type: EXPERIMENTAL
Intervention: Baclofen 25 micrograms
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baclofen 50 micrograms
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baclofen 100 micrograms
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6240568

Group type: COMPARATOR
Intervention: GRF1-44
Number of subjects: 5

Group type: COMPARATOR
Intervention: GRF1-40
Number of subjects: 5

Group type: COMPARATOR
Intervention: GRF1-29
Number of subjects: 5

Group type: COMPARATOR
Intervention: GRF1-44 (administered over 2 days in 6- and 18-h intervals)
Number of subjects: 5
Study: 30309789

Group type: EXPERIMENTAL
Intervention: School-based health education plus mindfulness training (HE-MT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Health education plus attention control (HE-AC)
Number of subjects: 53
Study: 29200185

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: AOM of other bacterial etiology
Number of subjects: 831

Group type: COMPARATOR
Intervention: No bacteria detected at AOM
Number of subjects: 831

Group type: COMPARATOR
Intervention: No early AOM
Number of subjects: 831
Study: 27509949

Group type: EXPERIMENTAL
Intervention: Radioguided occult lesion localization (ROLL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wire guided localization (WGL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 60

Group type: COMPARATOR
Intervention: WGL
Number of subjects: 60
Study: 24767575

Group type: EXPERIMENTAL
Intervention: Usual care with additional inspiratory muscle training intervention
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248
Study: 22844527

Group type: EXPERIMENTAL
Intervention: Plasma CatS levels (total, active, and pro‐CatS) in AAA patients
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Plasma cystatin C levels in AAA patients
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Correlation of plasma CatS levels with aortic diameter and lowest ABI
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Correlation of plasma cystatin C levels with aortic diameter and lowest ABI
Number of subjects: 676
Study: 20346181

Group type: EXPERIMENTAL
Intervention: Bojungikgitang
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Banhabaekchulchonmatang
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18653285

Group type: EXPERIMENTAL
Intervention: 20 mg memantine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15982350

Group type: EXPERIMENTAL
Intervention: One dose of influenza vaccine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Two doses of influenza vaccine
Number of subjects: 70
Study: 12816768

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP diet: 27% energy as protein, 44% as carbohydrate, 29% as fat)
Number of subjects: 57
Study: 9836012

Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7633106

Group type: EXPERIMENTAL
Intervention: Fast spin-echo (FSE) technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional spin-echo (CSE) technique
Number of subjects: 25
Study: 2923957

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study: 979226

Group type: EXPERIMENTAL
Intervention: Active recuperation (300 kpm/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Passive recuperation (quiet sitting)
Number of subjects: 13
Study: 29150782

Group type: EXPERIMENTAL
Intervention: GN2O (70% N2O in 30% oxygen)
Number of subjects: 100

Group type: COMPARATOR
Intervention: GO2 (air in 30% oxygen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GN2O
Number of subjects: 100
Study: 26837431

Group type: EXPERIMENTAL
Intervention: Early home-supported discharge service
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study: 25782764

Group type: EXPERIMENTAL
Intervention: GLYX-13 (5 or 10 mg/kg IV)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 23650780

Group type: EXPERIMENTAL
Intervention: BOMT1 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 2 x 500 mg, tetracycline 2 x 500 mg; for 14 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BOMT2 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 3 x 500 mg, tetracycline 4 x 500 mg; for 14 days)
Number of subjects: 90
Study: 21085598

Group type: EXPERIMENTAL
Intervention: Non-vocal test tones (piano and pure tones)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vocal test tones (natural and synthesized voices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Starting music lessons by age 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Starting music lessons on piano at a later age
Number of subjects: 0
Study: 17626135

Group type: EXPERIMENTAL
Intervention: Forearm support board
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Alternative mouse
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional mouse
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Alternative mouse plus forearm support board
Number of subjects: 206
Study: 16337372

Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treosulfan
Number of subjects: 0
Study: 14761119

Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 32
Study: 11289483

Group type: EXPERIMENTAL
Intervention: NPH insulin combined with glibenclamide (n = 19)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: NPH insulin combined with metformin (n = 17)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: NPH insulin combined with glibenclamide and metformin (n = 17)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Morning administration of NPH insulin (n = 23)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: NPH insulin therapy
Number of subjects: 81
Study: 9272791

Group type: EXPERIMENTAL
Intervention: Phantom limb pain
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Kinesthetic and kinetic phantom limb sensations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stump pain
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Telescoping of phantom limb
Number of subjects: 32
Study: 8153780

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.75% etidocaine
Number of subjects: 20
Study: 3217756

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 200 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1858634

Group type: EXPERIMENTAL
Intervention: Treadmill tests (Bruce, Balke, and ramp)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer tests (50 W/stage, 25 W/stage, and ramp)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Changes in protocol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: V slope method of detection
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall intraclass correlation coefficient for VO2 at the ATge among three reviewers
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall intraclass correlation coefficient for VO2 at the ATge among three protocols
Number of subjects: 23
Study: 409824

Group type: EXPERIMENTAL
Intervention: Low-dose continuous intravenous insulin infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-dose intermittent subcutaneous injections
Number of subjects: 20
Study: 31907018

Group type: COMPARATOR
Intervention: Routine antenatal ultrasound scan < 25 weeks during routine care and a second standard ultrasound scan at the research site within 2 weeks.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Routine antenatal ultrasound scan and an additional ultrasound scan < 25 weeks at the research site, with messages to promote parental attachment and healthy child development.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Routine ultrasound scan and two additional ultrasound scans at the research site, < 25 weeks and < 36 weeks, with messages to promote parental attachment and healthy child development.
Number of subjects: 100
Study: 30759112

Group type: EXPERIMENTAL
Intervention: High religiosity (attending religious services or activities at least 1-2 times a month)
Number of subjects: 20227

Group type: COMPARATOR
Intervention: Low religiosity
Number of subjects: 20227
Study: 30678594

Group type: EXPERIMENTAL
Intervention: Nested polymerase chain reaction (PCR) assay using six sets of primers developed from 20 candidate genes of U. virens.
Number of subjects: 0
Study: 26266877

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam (active placebo)
Number of subjects: 24
Study: 23974642

Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg once daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (switched to tafamidis)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tafamidis for 30 months
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 86
Study: 21419776

Group type: EXPERIMENTAL
Intervention: Canary pox recombinant vaccine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Whole inactivated vaccines
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subunit vaccines
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 44

Group type: COMPARATOR
Intervention: Annual vaccination
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Revaccination of horses with low antibody levels
Number of subjects: 44
Study: 19195817

Group type: COMPARATOR
Intervention: 4 cycles of epirubicin 75 mg/m² and docetaxel 75 mg/m²
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 6 cycles of epirubicin 75 mg/m² and docetaxel 75 mg/m²
Number of subjects: 176
Study: 17572614

Group type: EXPERIMENTAL
Intervention: Usual outpatient physiotherapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Spinal stabilization classes
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led pain management classes
Number of subjects: 212
Study: 15084646

Group type: EXPERIMENTAL
Intervention: Mentholated cigarettes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonmentholated cigarettes
Number of subjects: 14
Study: 11583478

Group type: EXPERIMENTAL
Intervention: GW420867X 300 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GW420867X 600 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GW420867X 900 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GW420867X 1200 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 9885721

Group type: EXPERIMENTAL
Intervention: Pressure garment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pressure garment (Control)
Number of subjects: 0
Study: 8299786

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated oral estrogen
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.05 mg transdermal 17 beta‐E2
Number of subjects: 35
Study: 2607268

Group type: EXPERIMENTAL
Intervention: 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.8 ml of 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Complete anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Potential anesthetic problems
Number of subjects: 30
Study: 30684002

Group type: EXPERIMENTAL
Intervention: High-dose RAI therapy (3700 MBq)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Low-dose RAI therapy (1110 MBq)
Number of subjects: 84
Study: 28632666

Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) treatment for 2 minutes a day at 100 KHz frequency
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-treated side (control)
Number of subjects: 19
Study: 25884517

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) course, two days duration
Number of subjects: 500

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention for 6 months)
Number of subjects: 500
Study: 23587561

Group type: EXPERIMENTAL
Intervention: Smartphone app (My Meal Mate)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Website (Weight Loss Resources)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 128
Study: 21570487

Group type: EXPERIMENTAL
Intervention: Exercise combined with vitamin D and calcium supplements
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (advised on benefits of exercise but not prescribed exercise)
Number of subjects: 60
Study: 19694184

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as ER capsules
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as plain capsules
Number of subjects: 8

Group type: COMPARATOR
Intervention: Budesonide (3 mg) without grapefruit juice
Number of subjects: 8
Study: 16973647

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%, 1 ml kg(‐1) with fentanyl 1 microg kg(‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%, 1 ml kg(‐1) with saline
Number of subjects: 36
Study: 12720586

Group type: EXPERIMENTAL
Intervention: Erythorbic acid (1 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ascorbic acid supplementation (0.5 g/d for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 20
Study: 11139102

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.1 microg/kg/min) plus intrathecal morphine (8 microg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil infusion (0.3 microg/kg/h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion plus intrathecal morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil infusion
Number of subjects: 40
Study: 9417395

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg, abrupt or progressive withdrawal
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg, abrupt or progressive withdrawal
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo, abrupt or progressive withdrawal
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal (with or without hydroxyzine)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Progressive withdrawal (with or without hydroxyzine)
Number of subjects: 154
Study: 1348430

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (dosage changed)
Number of subjects: 0
Study: 4064575

Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External chest wall compression (ECWC)
Number of subjects: 0
Study: 31161347

Group type: EXPERIMENTAL
Intervention: GDF-15 (increased levels)
Number of subjects: 1184305
Study: 30045274

Group type: EXPERIMENTAL
Intervention: Knowledge-based iterative model reconstruction (IMR)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Hybrid iterative reconstruction (HIR)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IMR with reduced tube voltage (80 kVp)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IMR at 100 kVp
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard 120-kVp protocol
Number of subjects: 101
Study: 26054422

Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 36
Study: 25530160

Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 1 mm depth
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 3 mm depth
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 5 mm depth
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 7 mm depth
Number of subjects: 15
Study: 22955340

Group type: EXPERIMENTAL
Intervention: Circulating 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Circulating 1,25-dihydroxyvitamin D (1,25(OH)2D)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Vitamin D pathway polymorphisms
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Stratified results by prostate cancer grade (high grade or low grade)
Number of subjects: 490
Study: 20456970

Group type: EXPERIMENTAL
Intervention: Reduction aortoplasty with patch augmentation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Modified David type repair with patch augmentation
Number of subjects: 66
Study: 17900775

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 101
Study: 15929047

Group type: EXPERIMENTAL
Intervention: Sparse pattern pulse stimulation for dichoptic multifocal visual evoked potentials (mfVEPs)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional mfVEP stimulus
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sparse mfVEPs
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Contrast reversal
Number of subjects: 77
Study: 12850864

Group type: EXPERIMENTAL
Intervention: Metformin, 850 mg twice daily throughout the cycle
Number of subjects: 161

Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling
Number of subjects: 161
Study: 10483810

Group type: EXPERIMENTAL
Intervention: Fatigue protocol consisting of 30 isometric maximal voluntary contractions (5s on, 5s off) followed by three maximal isometric knee extensions.
Number of subjects: 19
Study: 8998891

Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg followed by 30 mg)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Meperidine (100 mg or placebo)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 244
Study: 2007041

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg IV
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg IV and Metoclopramide 10 mg IV
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Group 1 and Group 2)
Number of subjects: 80
Study: 6269192

Group type: EXPERIMENTAL
Intervention: Tiapride infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0